PanTher Therapeutics

PanTher Therapeutics, Inc.

26 Investors
Oncology Therapeutics
Austin, TX

PanTher Therapeutics, Inc. is a clinical-stage oncology company that focuses on revolutionizing cancer treatment through localized therapy. By addressing the inefficiencies of systemic drug delivery, PanTher aims to enhance cancer therapies and minimize side effects for patients.

Products & Team

PTM-101

Oncology therapySeed

PTM-101 is an innovative, absorbable polymer film designed to deliver paclitaxel, a potent chemotherapy agent, directly to the peritumoral region. This targeted delivery method allows for sustained, high-dose administration while avoiding the systemic side effects typically associated with chemotherapy.

Value Proposition

PTM-101 addresses the limitations of systemic chemotherapy by ensuring that a significantly higher concentration of therapeutic agents reaches the tumor site, leading to improved efficacy and reduced toxicity.

Pain Points

The inefficiency of systemic chemotherapy, the limited drug reach to tumor sites, and the associated systemic side effects that affect patient quality of life.

Flexible polymer film designContinuous high-dose delivery directly to tissuesReduces systemic side effects of traditional chemotherapyUtilizes proprietary Sagittari™ platform for customization
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
Austin, TX
Primary headquarters

Funding History

Total Raised:
$3.0M
E

Equity, Option to Acquire Offering

March 2025
$5.0M
Target
Progress
60%
Raised
$3.0M
Target
$5.0M
#000164404525000003